Leone R J, Friedrichs G S, Merrill G F
Department of Biological Sciences, Rutgers, State University of New Jersey, New Brunswick 08903-0231.
J Appl Physiol (1985). 1993 Apr;74(4):1543-8. doi: 10.1152/jappl.1993.74.4.1543.
Twenty-six beagles of either sex, weighing 10.4 +/- 0.3 kg, were used to investigate the role of adenosine in the genesis of ventricular arrhythmias during systemic hypoxia. After instrumentation dogs were randomly assigned to one of four treatment groups: 14 dogs were pretreated before hypoxia with adenosine deaminase (n = 7, group I) or its vehicle (n = 7, group II) while 12 other dogs were pretreated with the A1 selective adenosine receptor antagonist BW A1433U (n = 6, group III) or its vehicle (n = 6, group IV). Each dog was exposed to a 3-min period of hypoxic ventilation [3% O2-5% CO2-92% N2; PO2 in arterial blood 96 +/- 3 Torr (before hypoxia), 21 +/- 1 Torr (during hypoxia)]. The percentages of ventricular ectopic beats (19) experienced in the four groups after 3 min of hypoxia were 21 +/- 10% (group I, P < 0.05 relative to group II), 50 +/- 2% (group II), 15 +/- 8% (group III, P < 0.05 relative to group IV), and 42 +/- 7% (group IV). Ventricular bigeminy, the most prominent arrhythmia seen in this study, was significantly reduced by adenosine deaminase and BW A1433U. No significant differences in other monitored cardiovascular variables were seen between adenosine deaminase and BW A1433U treatment groups and their corresponding vehicles. These findings implicate endogenous adenosine as an arrhythmogenic mediator during hypoxia and point to a mechanism involving the A1 adenosine receptor.
选用26只体重为10.4±0.3千克的雌雄比格犬,用于研究腺苷在全身缺氧期间室性心律失常发生中的作用。在植入仪器后,将犬随机分为四个治疗组之一:14只犬在缺氧前用腺苷脱氨酶预处理(n = 7,I组)或其赋形剂(n = 7,II组),而另外12只犬用A1选择性腺苷受体拮抗剂BW A1433U预处理(n = 6,III组)或其赋形剂(n = 6,IV组)。每只犬接受3分钟的低氧通气[3% O2 - 5% CO2 - 92% N2;动脉血PO2在缺氧前为96±3 Torr,缺氧期间为21±1 Torr]。缺氧3分钟后,四组中出现的室性早搏(19)百分比分别为21±10%(I组,相对于II组P < 0.05)、50±2%(II组)、15±8%(III组,相对于IV组P < 0.05)和42±7%(IV组)。室性二联律是本研究中最显著的心律失常,腺苷脱氨酶和BW A1433U可使其显著减少。腺苷脱氨酶和BW A1433U治疗组与其相应赋形剂组之间在其他监测的心血管变量方面未观察到显著差异。这些发现表明内源性腺苷在缺氧期间是一种致心律失常介质,并指出了一种涉及A1腺苷受体的机制。